TrialCurrent oncology (Toronto, Ont.)2026

Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.

Panagiotis Ntellas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.